xml version="1.0" encoding="US-ASCII"?         

UNITED STATES  

SECURITIES AND EXCHANGE COMMISSION  

Washington, D.C. 20549  

FORM 8-K  

CURRENT REPORT  

Pursuant to Section 13 or 15(d) of  

the Securities Exchange Act of 1934  

Date of Report (Date of earliest event reported): January 13, 2020 (January 13, 2020) 

REGENERON PHARMACEUTICALS, INC.  

(Exact name of registrant as specified in its charter)  

New York  

(State or other jurisdiction of incorporation)  [DATA_TABLE_REMOVED] 

Registrant’s telephone number, including area code: (914) 847-7000 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act: [DATA_TABLE_REMOVED] 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company o 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o 

Item 2.02. Results of Operations and Financial Condition. 

On January 13, 2020, at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California (the “2020 J.P. Morgan Healthcare Conference”), Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron, are providing a corporate update. The presentation includes information regarding the Company’s preliminary (unaudited) U.S. net product sales of EYLEA® (aflibercept) Injection of approximately $4.64 billion for the full year 2019 (based on preliminary (unaudited) fourth quarter 2019 U.S. net product sales of EYLEA of approximately $1.22 billion). 

Item 7.01. Regulation FD Disclosure. 

The information set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference herein. 

On January 13, 2020, at the 2020 J.P. Morgan Healthcare Conference, Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron, are providing a corporate update. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this

 Item 7.01. 

The information included in Item 2.02 and the information included or incorporated in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. 

Item 9.01. Financial Statements and Exhibits. 

(d) Exhibits. 

 99.1   Presentation by Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc., and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron Pharmaceuticals, Inc., at the 38th Annual J.P. Morgan Healthcare Conference.  

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

   REGENERON PHARMACEUTICALS, INC.    

/s/ Joseph J. LaRosa   

   Joseph J. LaRosa   

   Executive Vice President, General Counsel and Secretary   

Date: January 13, 2020 

  false 0000872589      0000872589   2020-01-13 2020-01-13